Hansa Biopharma: Ends 2024 on a soft note - Redeye

After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European experience, reimbursement and guidelines.

Länk till analysen i sin helhet: https://www.redeye.se/research/1074106/hansa-biopharma-ends-2024-on-a-soft-note?utm_source=finwire&utm_medium=RSS